• In September 2024, Foremost announced an option agreement with Denison Mines for 10 uranium projects in Saskatchewan’s Athabasca Basin.
• The company has aggressive exploration plans across its 330,000-acre uranium portfolio, with both shallow and deep targets.
• The Athabasca Basin is known for hosting some of the richest uranium deposits in the world, with strong infrastructure supporting exploration.
• Foremost’s partnerships with Denison Mines and local geological firms, along with its strong management team, position it well for future success.
• The company also holds a secondary portfolio of lithium projects, covering over 50,000 acres, providing additional long-term growth potential.

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT), formerly Foremost Lithium Resource & Technology Ltd., is an emerging North American energy exploration company focused on supporting the clean energy transition. Foremost holds an option to acquire an interest in 10 prospective uranium properties, covering over 330,000 acres in the uranium-rich Athabasca Basin of Saskatchewan.

The company aims to address the growing demand for uranium, a critical element in global energy transition efforts. In partnership with Denison Mines (NYSE American: DNN), Foremost is pursuing a disciplined and dynamic exploration strategy. Foremost’s mission is to make significant discoveries through active exploration of its promising, underdeveloped land holdings in the Athabasca Basin. Its uranium portfolio includes projects at various stages of exploration, from grassroots initiatives to advanced, drill-ready targets.

As the world shifts toward a clean energy future, uranium will play a key role as a low-cost, emission-free fuel for electricity generation. Foremost’s development plans aim to provide low-cost uranium solutions, capitalizing on the global movement to decarbonize power grids.

In addition to its uranium assets, Foremost holds a secondary portfolio of lithium projects, spanning more than 50,000 acres across Manitoba and Quebec.

Foremost is headquartered in Vancouver, British Columbia.

Projects

Foremost’s portfolio, under its option agreement with Denison Mines, includes 10 properties, many located near high-profile uranium operations like the McClean Lake mill and Cigar Lake mine. Seven of these properties are situated in the eastern portion of the Athabasca Basin, close to well-established infrastructure, while three lie in the northwestern portion of the basin – an area with high potential for new discoveries but little previous exploration.

Through the option agreement, Foremost may earn up to 70% of Denison’s interest in the properties. Denison currently owns 100% of nine properties. The agreement includes three phases during which Foremost must issue shares to Denison, appoint Denison representatives to its board, provide cash or share payments, and incur specific exploration expenditures to increase its ownership stake.

Market Opportunity

According to RationalStat, the global uranium mining market was valued at $8.09 billion in 2023 and is projected to grow to $11.38 billion by 2030, with a CAGR of over 5%.

Uranium, used in nuclear reactors, produces energy through nuclear fission and is considered a clean energy source as it emits no greenhouse gases during operation. The push to reduce carbon emissions and combat climate change is driving the demand for nuclear energy, and thus, uranium.

The uranium market is also poised for growth due to the phasing out of fossil fuels, mine closures, production disruptions, and geopolitical factors such as trade sanctions on Russia and civil unrest in Niger, which have highlighted the urgency for reliable uranium supplies.

Canada, producing about 15% of the world’s uranium annually, is the second-largest global uranium producer, after Kazakhstan.

Management Team

Jason Barnard, CEO, President, and Executive Board Member of Foremost, has over 31 years of capital markets experience. He has been directly involved in raising over $500 million for mining and exploration companies. Mr. Bernard began his career with McDermid St. Laurence Securities and later worked at Canaccord Genuity. He has been with Foremost since 2016 and is its largest shareholder. He holds a bachelor’s degree in economics from Carleton University.

Dong Shim, CPA, CA, serves as CFO. He is a partner at Shim & Associates LLP and is registered as a CPA in British Columbia and Illinois. Mr. Shim brings extensive accounting and auditing expertise, having worked with both U.S. and Canadian junior mining and tech companies.

Christina Barnard, COO, has over 20 years of experience in business management, media and marketing. Her career includes a decade as a senior marketing and media advisor for a national public company and roles in corporate communications and strategy for several public companies.

For more information, visit the company’s website at https://foremostcleanenergy.com.

NOTE TO INVESTORS: The latest news and updates relating to FMST are available in the company’s newsroom at https://ibn.fm/FMST

The success of the NECANN 2023 convention has paved for a larger NECANN 2024 convention. The convention will be held at the spacious NYS Fairgrounds in Syracuse accommodating a mammoth number of traders, enthusiasts, growers, marketers, entrepreneurs, and investors from the cannabis and hemp spectrum.

One of the most coveted cannabis conventions, NECANN events are known for offering the best educational, interactive and business platform for cannabis enthusiasts. They broaden the horizons of every region they visit, offering phenomenal opportunities to the local business community.

This time, the NECANN event will be held in the Empire State on October 25-26, 2024, once again providing a common forum for discussion, exploration, networking, and collaborative deals on recreational and medicinal marijuana.

Exhibitors from New York State and other areas can set up booths and exhibit their products and services at the NYS Fairgrounds. They can showcase their innovative ideas to cannabis influencers, leaders and some of the biggest investors in the cannabis industry.

Attendees can create a personalized schedule for themselves, attending only those sessions that they have ‘bookmarked’. The convention will host interactive sessions, keynote speaker sessions, and discussion panels where experts navigate pivotal topics of the cannabis and hemp landscape. They will speak about the latest regulatory changes, Cannabis operator accounting, finance technology, cybersecurity, and so on.

Jack Grover, Founder & CEO of Grove Bags, will share insights into the art and science of cannabis preservation. Experts will also throw light on the justification and strategies for amending tax returns to recapture lost deductions. Presenter Brooke Anderson will take the audience on a journey describing her tryst with cannabis and its healing impact on her life and health.

To learn more, please visit https://ibn.fm/xghsD

Solution providers and innovators of the pharma and healthcare industry, as well as experts in clinical trials, are invited to attend the 21st Biopharma Clinical Trials Nexus at the Holiday Inn Piscataway, Somerset, in New Jersey. This is an invite-only event that will be held from October 22, 2024, to October 23, 2024.

BioPharma Nexus focuses on creating synergies between leading pharmaceutical and biotechnology entities, along with service providers. Their objective is to provide high-quality healthcare to patients all over the globe. At the BioPharma Nexus conferences, players can explore, discover, and generate partnerships for scientific and healthcare collaborations. 

New Jersey has been selected as the venue for hosting the event owing to several reasons. New Jersey is a powerful pharmaceutical corridor and has been pivotal in supporting biotech innovations. Experts and leaders of the biotech & pharma spectrum will attend the event to discuss useful insights on evolving healthcare and share effective strategies to overcome hurdles in clinical operations, patient-centricity, clinical outsourcing, and digital innovation. This event serves as a viable platform for clinical trial service providers to connect with industry leaders and engage in business collaborations.

The attendees at the conference will consist of senior executives and mid-level management from industries in clinical operations, digital health, patient outsourcing, and patient engagement in the US and Europe.

The event agenda consists of presentations by company executives where they showcase their innovative ideas, technology and goals. Aspiring newcomers as well as veterans will speak about their impeccable results in clinical trials. Eminent industry dignitaries will participate in panel discussions and roundtable talks where they delve into finding solutions and strategies for several industry issues. Attendees can engage with peers and brilliant industry minds during the networking breaks and lunch sessions.

To learn more, please visit https://ibn.fm/nRQpt.

• DiPasquale was featured in publications discussing his journey from the tech industry to entrepreneurship with Epic Golf Club and now GolfLync.
• Since its inception in 2018, Epic Golf Club, partnering with 200 private clubs in 43 states, plus first-rate clubs in 13 countries, has become known for its exclusive membership and five-star experiences, now having grown to 1,000 members.
• DiPasquale has brought that same sense of golfing dedication to GolfLync, an unmatched social networking platform, uniting golf enthusiasts in a top-tier golfing community of players and clubs.

GolfLync CEO and Co-Founder Noah DiPasquale, a visionary known for reimagining industries, is dedicated to providing an epic experience to all members of his exclusive Epic Golf Club, and now fostering a dynamic golfing community with GolfLync, a pioneering golf social networking platform where golf enthusiasts can come together and enjoy the game at its highest level.

In a series of recent articles highlighting DiPasquale’s journey from the tech industry to entrepreneurship and the unique experience offered by Epic Golf Club, the entrepreneur discusses what sets his projects apart in the golfing community, what inspired him to create Epic Golf Club, as well as the development and latest plans for GolfLync.

DiPasquale was born in California and moved to Chapparel, Arizona, at the age of five. Raised in modest circumstances with no golf courses or family players nearby, he discovered golf later in life. After graduating from Northern Arizona University, he dabbled in the sport with friends but didn’t pursue it seriously until years later with business clients. In 2016, DiPasquale launched his own management consulting firm, which he sold in 2018 to focus fully on his new venture, Epic Golf Club (https://ibn.fm/mTcVE).

Headquartered in Scottsdale, Epic Golf Club quickly gained a reputation for prestige and exclusivity. The club’s unique reciprocal membership model allows members to play at the finest private golf courses around the world, fostering a community of golfing elites. “The inspiration behind Epic Golf Club was to create a community where golf enthusiasts could come together and enjoy the game at its highest level,” DiPasquale said (https://ibn.fm/piSh1). Epic Golf Club partners with 200 private clubs in 43 states plus first-rate clubs in 13 countries including the Netherlands, Germany, China, Morocco, Canada, and Mexico.

DiPasquale further explained that what sets Epic Golf Club apart is an unwavering commitment to delivering a white-glove, five-star experience to members. “We wanted to offer more than just private course experiences,” he said. “We aimed to provide a full-fledged, luxury experience that includes exclusive member-only events, white-glove concierge services, and a sense of strong camaraderie among our members.”

Although exclusive, the demand to join Epic Golf Club has grown. Beginning with just 20 people in 2019, the club now has 1,000, and receives about 1,500 applications every month, out of which only 20 are selected. And as the membership grows, the number of those accepted will decrease, DiPasquale explained.

Beyond business, DiPasquale also discussed his philanthropic work through the Epic Foundation, which supports Folds of Honor, HopeKids and Youth on Course, aiming to support families of disabled or fallen service members, give hope to children with severe medical conditions, and provide inclusive golf training for the next generation of golfers (https://ibn.fm/BqlbZ). Epic also offers a student athlete scholarship for two high school seniors entering college every year. “The Epic Foundation lies at the core of Epic Golf Club’s values and is incredibly important to me personally,” DiPasquale said. “Even before Epic took off, prioritizing community support was paramount. To qualify as a member of the club, sharing these values is essential.”

DiPasquale has brought the same love for golf, and the desire to build a strong community for golfers, to GolfLync. Working much like a dating app for true golf lovers, GolfLync matches games and players, helping golfers grow their networks and find other players with similar interests and on-course preferences. Not surprisingly, the app has proven successful, with 140,000 downloads in its first 12 months. Following the same model, DiPasquale, together with Michael Quiel, a finance veteran known for his resilience and commitment to justice, have now launched SportLync, aiming to connect athletes worldwide across various sports, including tennis and hiking, with advanced AI-driven tools.

You can download the GolfLync app using the following text-anchored links:

• Android: GolfLync – Apps on Google Play 
• iPhone: GolfLync 

For more information about GolfLync, visit GolfLync, download the app, and connect with community on Facebook, X and LinkedIn. 

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• This year enrollment in Medicare Advantage plans reached 32.8 million members, representing 52% of all Medicare recipients.
• Medicare Advantage plans typically integrate various health services under one umbrella.
• Astiva Health’s approach helps members manage existing health conditions and also focuses on promoting overall wellness.

Over the past two decades, Medicare Advantage has transformed from a niche option into a primary choice for millions of seniors across the United States. Medicare Advantage plans bundle Part A, Part B and sometimes Part D coverage into one plan, along with often offering extra benefits that original Medicare doesn’t cover. A fast-growing Medical Advantage prescription drug (“MAPD”) plan, Astiva Health offers a type of Medicare Advantage plan with prescription drug coverage, so members have no need for a separate Part D plan.

As of 2024, enrollment in Medicare Advantage plans has reached an unprecedented 32.8 million beneficiaries, representing 52% of all Medicare recipients, reported a recent Kaiser Family Foundation report (https://ibn.fm/91O0t). This statistic illustrates a significant increase in popularity, as enrollment in Medicare Advantage has more than doubled since 2004. Factors driving this rise include an aging population, rising healthcare costs, and the growing appeal of the added benefits these plans provide.

One of the primary advantages of Medicare Advantage plans is their ability to offer a more holistic approach to healthcare. Unlike original Medicare, which can sometimes lead to fragmented care, Medicare Advantage plans typically integrate various health services under one umbrella. This can include additional coverage for dental, vision and hearing services, as well as wellness programs and preventive care initiatives. The integration of these services makes it easier for members to manage their healthcare and access the necessary resources.

Another key element contributing to the growth of Medicare Advantage is the emphasis on cost effectiveness. Many members find that these plans provide lower out-of-pocket expenses compared to traditional Medicare. With a fixed monthly premium and capped out-of-pocket costs, members have a clearer understanding of their healthcare expenses. The allure of predictable costs and additional services makes Medicare Advantage an appealing option for seniors navigating the complexities of healthcare.

In this evolving market, companies such as Astiva Health are stepping up to meet the growing demand for quality Medicare Advantage plans. Astiva Health offers a range of options that prioritize member satisfaction and comprehensive care. Their plans are designed to cater to the unique needs of seniors, providing access to extensive networks of healthcare providers and specialized services.

Astiva Health stands out by emphasizing preventive care and chronic disease management. The company’s approach not only helps its members manage existing health conditions but also focuses on promoting overall wellness. By offering personalized support and resources, Astiva Health ensures that members are equipped to make informed decisions about their healthcare.

The increasing enrollment in Medicare Advantage is indicative of a broader trend toward value-based care, where the focus is on improving health outcomes rather than merely providing services. As members become more informed and engaged in their healthcare choices, the demand for plans that offer comprehensive and coordinated care will likely continue to rise.

Organizations such as Astiva Health play a crucial role in this upward trend by providing high-quality Medicare Advantage plans that cater to the diverse needs of older adults. As this surge continues, the future of Medicare Advantage looks bright, offering hope and health to millions of seniors nationwide.

Astiva Health is committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California. Astiva Health is also eyeing expansion into Northern California and beyond.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva

The 3rd Annual Roth Healthcare Opportunities Conference will be held at the Metropolitan Club in New York, NY on October 9, 2024. Healthcare professionals, executives, businesses, industries, and investors of the allied healthcare sectors are invited for a full day of networking, learning and collaboration with peers and industry leaders.

This event focuses on an extensive format where executives and professionals from the Biotechnology, Brain Disorders, Medical Technologies, Oncology Therapeutics, and Pharmaceuticals sectors, gain deep insights into each other’s work portfolios.

The conference will cover small group meetings where companies and investors can interact and get a clear understanding of respective goals and work. Experts will conduct discussions on Themed Industry Panels with selected companies. The small group meetings will be in a 1-on-1 format, consisting of 25-minute management-investor meetings with extensive interaction.

The Roth conference is designed to provide a robust forum for upcoming healthcare industries and service providers to showcase their innovative ideas, technology, products, and services. C-level executives representing public and private healthcare can connect with investors for collaborative discussions.

This conference offers a tremendous opportunity for healthcare executives to present their unique company qualities to a crowd consisting of top investors and industry leaders. These meetings could well pave the way to discover new avenues and seal lucrative deals.

Recreational events are also a part of Roth events to encourage interaction among the attendees. The lunch panel will be followed by a cocktail reception.

To learn more, please visit https://ibn.fm/1LfAT

• Bringing a well into production involves several critical steps, including drilling, completion and the establishment of infrastructure to extract and transport the gas.
• Recently Trillion Energy announced that its Akcakoca-3 well at the SASB Gas Field has been put into production.
• Company reports that all wells but one have been put on production or flow tested to determine if gas is present and capable of production.

Natural gas has emerged as a crucial component of the global energy landscape, serving as a cleaner alternative to coal and oil. For a natural gas company, such as Trillion Energy International (CSE: TCF) (OTCQB: TRLEF), bringing a well into production is a pivotal step that not only signifies operational progress but also leverages the potential for economic growth, environmental sustainability and energy security.

Bringing a well into production involves several critical steps, including drilling, completion and the establishment of infrastructure to extract and transport the gas. This process transforms a previously untapped reservoir of natural gas into a functioning source of energy. The successful production of natural gas involves not only the technical aspects of drilling and extraction but also adherence to regulatory requirements, environmental considerations and market demand.

Once a well is in production, it starts generating revenue for the company. This can significantly impact the company’s financial health, allowing for reinvestment into further exploration and development, technological advancements and enhanced operational efficiencies. A well’s production capability is often measured in terms of its output volume, typically expressed in thousands of cubic feet per day (“MCF/D”). Higher production rates can lead to increased profitability, making the efficient operation of gas wells crucial.

Today, natural gas is recognized as a promising business sector for several reasons. First, the global demand for cleaner energy sources continues to rise. As countries transition away from coal and oil, natural gas is often seen as a bridge fuel, facilitating the shift toward renewable energy sources while maintaining energy reliability.

Trillion Energy, a Canadian oil and gas exploration and production company, is working to become a leader in this sector. Recently the company announced that its Akcakoca-3 well at the SASB Gas Field has been put into production (https://ibn.fm/XYZZm). According to the announcement, 11 meters of gas pay was perforated in the Akcakoca-3 well in July, but due to delayed pressure buildup, it was not initially produced. However, last month the well head pressure (“WHP”) for Akcakoca-3 had increased to 616 psi and the well was put into production. Trillion Energy reported that initial production flow rates were 4.28 million cubic feet per day (“MMcf/d”), which increased to 4.66 MMcf/d with WHP increasing to 645 psi. At the same time, Trillion Energy’s Alapli-2 well was opened to test pressure, resulting in gas flow to surface. However, the well is not producing gas in significant quantities at this time, so production is pending installation of velocity strings.

“We are thrilled with the strong performance of Akcakoca-3 and the successful flow tests at Alapli-2,” said Trillion Energy CEO Arthur Halleran. “All the wells except Bayhanli-2 have now been put on production or flow tested to ascertain if gas is present and capable of production in the 4-1/2-inch production tubing. This confirms that once the 2-3/8-inch is installed in the wells the gas will flow in a predictable and stable manner.”

Putting a natural gas well into production is a multifaceted process that is key for the success of a company operating in this space. With the growing global focus on sustainable energy, investing in natural gas production represents not only a lucrative opportunity but also a pathway to a more secure and environmentally responsible energy future.

Trillion Energy International is focused on oil and natural gas production for Europe and Türkiye with natural gas assets in Türkiye. The company is 49% owner of the SASB natural gas field, a Black Sea natural gas development, and has a 19.6% interest (except three wells with 9.8%) in the Cendere oil field.

For more information, visit www.TrillionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to TRLEF are available in the company’s newsroom at https://ibn.fm/TRLEF

• Sophie Ames will lead the company’s human capital innovation strategy to support its next stage of growth.
• Her prior experience includes leadership roles at top public and private technology and services companies, including Mitel, ServiceMax, Avaya and more.
• D-Wave CEO Dr. Alan Baratz said Ames’ proven 25-year track record will help D-Wave’s employee value proposition stand out in a highly competitive labor marketplace.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently announced the appointment of a new chief human resources officer to its executive team (https://ibn.fm/elbbu).

The new chief human resources officer, Sophie Ames, brings more than 25 years of broad international experience in the human resources field. Ames has held leadership roles with various top public and private international technology and services companies, such as Mitel, ServiceMax, Veritas Technologies LLC, Avaya, Amdocs, and Thomson Legal & Regulatory, establishing a strong track record for building agile, high performance HR teams and scaling organizations for growth.

In her new role at D-Wave, Ames will spearhead the company’s global human capital innovation strategy designed to help support the company’s next stage of growth. This includes talent acquisition, learning and development, organizational effectiveness, compensation and benefits, and HR operations. She will focus on building the connection between the company’s performance, people and processes across the entire employee lifecycle engagement.

“I couldn’t be more excited to join D-Wave and be part of a company leading the next technology innovation revolution. It is an incredible opportunity to help shape the future of an industry and to bring the human capital function to the forefront of growth,” said Ames.

D-Wave CEO Dr. Alan Baratz echoed this excitement in welcoming Ames to D-Wave, noting, “Sophie’s proven track record and experience will add strategic value to the human resources function as we continue to build and differentiate D-Wave’s employee value proposition in a distinctive labor marketplace.”

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Leaders, professionals and executives from the Quantitative Investment spectrum are invited to attend the Quant Strats Conference, being held October 8, 2024, at the Convene 22 Bishopsgate, London. The focus of the event will be the exploration of new avenues to generate Alpha, and how the rapidly changing global economy impacts the investment landscape.

Experts in Quantitative Investments will gather at the Quant Starts Conference to discuss topics of most relevance, including meta-data, and the application of AI, ML, NLP, and LLMs in financial markets, as well as exploring key alternative assets for alpha generation, and how to build high-performing teams and strong portfolios.

The key themes will be:

• Creating and managing a portfolio in the current economic and political scenario
• Determining what asset classes perform in volatile markets
• Securing portfolios and funds from the unpredictable movement of equities and bonds
• Incorporating the most cutting-edge technologies to generate Alpha

An interactive discussion will be hosted by Michael Steliaros, Global Head of Portfolio Engineering and Trading, ADIA, focusing on what institutional investors must look for when selecting a fund manager. Among other important sessions of the conference is a panel discussion on Data Sourcing and Strategy.

Attendees can leverage the reach of the conference platform to network with 250 global quant leaders. Over 50 eminent dignitaries leading the way in Quantitative Investment will host speaker sessions. These experts from Goldman Sachs, Robeco, Point72, ADIA, and others, will bring in fresh insights and share their best views on the current trends in the market.

With just under 60% of the audience from the buying side and an audience consisting of data teams, quant traders and portfolio managers, the event will offer several collaboration opportunities.

To know more, please visit https://ibn.fm/6a55t

• Annovis Bio recently filed three new patents covering combinations of buntanetap, its lead compound, with a GLP-1 agonist (such as dulaglutide/Trulicity) and with PDE5 inhibitors (such as sildenafil/Viagra), as well as a combination of all three
• The company believes these combinations create a broader approach to treating neurodegenerative diseases
• Preclinical studies have demonstrated these combinations significantly improve cognition in Alzheimer’s mouse models
• Combinations of buntanetap with PDE5 inhibitors and GLP-1 agonists are now ready to enter phase 3 clinical studies (buntanetap is in phase 3, and a number of PDE5 inhibitors and GLP-1 agonists are already on the market)

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently filed three new patents (https://ibn.fm/wWksA). The patent applications seek protection for innovative combination therapies involving buntanetap that improve cognition beyond normal levels.

Specifically, the patent filings cover buntanetap combined with a glucagon-like peptide-1 (“GLP-1”) agonist, buntanetap combined with a phosphodiesterase 5 (“PDE5”) inhibitor, and a combination of all three. According to the company, these combinations create a multi-sided approach to treating neurodegenerative diseases.

The motivation to seek patent protection stems from the successes of recent preclinical studies, which have provided compelling results that demonstrate the strong potential for the combinations to enhance cognition. Data from these studies have shown that buntanetap combined with PDE5 inhibitors or GLP-1 agonists improves cognitive function in Alzheimer’s mouse models beyond levels observed in healthy controls.

Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis, noted, “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement.” Maria went on to state that the combination of buntanetap with Trulicity and Viagra has the potential to “restore cognition to healthy levels” and improve it “beyond normal level, offering new hope in the fight against dementia.”

According to an August 6 news release, buntanetap significantly amplifies the effects of Trulicity on memory and learning, leading to a “6- to 10-fold increase in efficacy,” according to Maria. The company observes that this synergy helps enhance treatment outcomes while simultaneously lessening potential side effects (https://ibn.fm/0zRY1).

Buntanetap targets neurodegeneration by inhibiting the production of various neurotoxic proteins, including TDP43, alpha-synuclein, tau, and amyloid beta. It improves the affected function in neurodegenerative diseases, enhances cognition in early AD patients, improves motor function and stops cognitive decline in PD patients.

The company’s recent Phase 2/3 study of buntanetap in patients with early (mild to moderate) AD showed a statistically significant improvement in cognition. The Phase 2/3 study gave the company valuable information for a planned Phase 3 pivotal trial (https://ibn.fm/sVv02). In addition, the company has separately completed a Phase 3 study of buntanetap in patients with early PD (https://ibn.fm/FIM3D).

“Since buntanetap has completed Phase 3 studies as a standalone treatment, and a number of GLP-1 agonists and PDE5 inhibitors are FDA-approved, these combinations are well positioned for Phase 3 human trials,” expressed Maria in the Sept. 30 news release announcing the patent filings.

The new patent applications are expected to further strengthen the company’s expansive intellectual property portfolio. Annovis currently has more than 35 total issued patents, plus plenty more pending applications in various jurisdictions, according to its latest Form 10-K filing (https://ibn.fm/YzxJB).

The issued patents and pending applications speak to the company’s resolve to “protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties,” as a source of its unique value to shareholders and competitive advantage.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS